Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes |
| |
Authors: | Wallin Jeffrey J Guan Jane Edgar Kyle A Zhou Wei Francis Ross Torres Anthony C Haverty Peter M Eastham-Anderson Jeffrey Arena Sabrina Bardelli Alberto Griffin Sue Goodall John E Grimshaw Kyla M Hoeflich Klaus P Torrance Christopher Belvin Marcia Friedman Lori S |
| |
Affiliation: | Department of Cancer Signaling and Translational Oncology, Genentech, Inc., South San Francisco, California, USA. jwallin@gene.com |
| |
Abstract: | The PTEN/PI3K pathway is commonly mutated in cancer and therefore represents an attractive target for therapeutic intervention. To investigate the primary phenotypes mediated by increased pathway signaling in a clean, patient-relevant context, an activating PIK3CA mutation (H1047R) was knocked-in to an endogenous allele of the MCF10A non-tumorigenic human breast epithelial cell line. Introduction of an endogenously mutated PIK3CA allele resulted in a marked epithelial-mesenchymal transition (EMT) and invasive phenotype, compared to isogenic wild-type cells. The invasive phenotype was linked to enhanced PIP(3) production via a S6K-IRS positive feedback mechanism. Moreover, potent and selective inhibitors of PI3K were highly effective in reversing this phenotype, which is optimally revealed in 3-dimensional cell culture. In contrast, inhibition of Akt or mTOR exacerbated the invasive phenotype. Our results suggest that invasion is a core phenotype mediated by increased PTEN/PI3K pathway activity and that therapeutic agents targeting different nodes of the PI3K pathway may have dramatic differences in their ability to reverse or promote cancer metastasis. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|